Safety of Gabapentin Prescribed for Any Indication in a Large Clinical Cohort of 571,718 US Veterans with and without Alcohol Use Disorder. by Rentsch, Christopher T et al.
Safety of Gabapentin Prescribed for Any Indication in a
Large Clinical Cohort of 571,718 US Veterans with and
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Christopher T. Rentsch , Kenneth L. Morford, David A. Fiellin , Kendall J. Bryant,
Amy C. Justice , and Janet P. Tate
Background: Gabapentin is prescribed for seizures and pain and has efficacy for treating alcohol
use disorder (AUD) starting at doses of 900 milligrams per day (mg/d). Recent evidence suggests safety
concerns associated with gabapentin including adverse neurologic effects. Individuals with hepatitis
C (HCV), HIV, or AUD may be at increased risk due to comorbidities and potential medication
interactions.
Methods: We identified patients prescribed gabapentin for ≥ 60 days for any indication between
2002 and 2015. We propensity-score matched each gabapentin-exposed patient with up to 5 gaba-
pentin-unexposed patients. We followed patients for 2 years or until diagnosed with (i) falls or
fractures, or (ii) altered mental status using validated ICD-9 diagnostic codes. We used Poisson
regression to estimate incidence rates and relative risk (RR) of these adverse events in association
with gabapentin exposure overall and stratified by age, race/ethnicity, sex, HCV, HIV, AUD, and
dose.
Results: Incidence of falls or fractures was 1.81 per 100 person-years (PY) among 140,310 gabapen-
tin-exposed and 1.34/100 PY among 431,408 gabapentin-unexposed patients (RR 1.35, 95% confidence
interval [CI] 1.28 to 1.44). Incidence of altered mental status was 1.08/100 PY among exposed and 0.97/
100 PY among unexposed patients, RR of 1.12 (95% CI 1.04 to 1.20). Excess risk of falls or fractures
associated with gabapentin exposure was observed in all subgroups except patients with HCV, HIV, or
AUD; however, these groups had elevated incidence regardless of exposure. There was a clear dose–re-
sponse relationship for falls or fractures with highest risk observed among those pre-
scribed ≥ 2,400 mg/d (RR 1.90, 95% CI 1.50 to 2.40). Patients were at increased risk for altered mental
status at doses 600 to 2,399 mg/d; however, low number of events in the highest dose category limited
power to detect a statistically significant association ≥ 2,400 mg/d.
Conclusions: Gabapentin is associated with falls or fractures and altered mental status. Clinicians
should be monitoring gabapentin safety, especially at doses ≥ 600 mg/d, in patients with and without
AUD.
Key Words: Gabapentin, Neurologic Effects, Electronic Health Records, Alcohol Use Disorder,
Chronic Hepatitis C, HIV Infection.
THE LIMITED E fficacy of current medication andcounseling strategies to treat alcohol use disorder
(AUD) has led to a search for new medications, especially
ones with which prescribers are comfortable. Gabapentin, an
anticonvulsant and structural analogue to gamma-aminobu-
tyric acid (GABA), is approved by the U.S. Food and Drug
Administration for treating partial seizure and postherpetic
neuralgia and has shown efficacy for the treatment of AUD
(Mason et al., 2014; Pani et al., 2014). Gabapentin is also
commonly prescribed off-label for peripheral neuropathy,
fibromyalgia, and other painful conditions (Kesselheim
et al., 2011; Shanthanna et al., 2017).
Recent evidence suggests that clinicians are comfortable
and familiar with gabapentin. A qualitative analysis examin-
ing attitudes toward gabapentin use for managing neuro-
pathic pain found that prescribers viewed gabapentin to be a
safe and nonaddictive medication with few drug interactions
(Ghinea et al., 2015). In 2016, 64 million gabapentin pre-
scriptions were dispensed making it the 10th most prescribed
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medication in the United States (IQVIA Institute, 2018). Pre-
scribing rates of gabapentin have increased considerably in
recent years partially due to promotion of gabapentin for
on- and off-label uses (Steinman et al., 2006) as well as the
perception that it represents a safe alternative to opioids for
treating chronic pain (Goodman and Brett, 2017).
However, gabapentin presents important safety concerns
including neurologic adverse effects, such as ataxia, dizziness,
and somnolence (Meng et al., 2014; Shanthanna et al., 2017;
Wiffen et al., 2017). This is of particular concern for popula-
tions who may be at increased risk for adverse effects, such
as individuals with hepatitis C (HCV), HIV, and AUD.
These patients may be at greater risk of neurologic adverse
events due to medical and psychiatric comorbidities and
potential medication interactions. As alterations in mental
status and coordination can lead to falls, fractures are a par-
ticular concern due to the association of HIV infection with
fragility fractures (Womack et al., 2011) and AUD with
osteoporosis and osteopenia (Berg et al., 2008).
Given the widespread prescribing of gabapentin and its
potential utility in decreasing alcohol consumption among
treatment-seeking and non–treatment-seeking populations
(Rentsch et al., 2019), we sought to determine its association
with events often linked with neurologic effects of dizziness,
ataxia, and somnolence among patients receiving gabapentin
for any indication, specifically falls or fractures (Ishida et al.,
2018) and altered mental status. We further assessed whether
these effects differed in demographic and clinical subpopula-
tions at higher risk for these events, including patients with
and without HCV, HIV, and AUD.
MATERIALS ANDMETHODS
Study Population
We used electronic health record (EHR) data available through
the US Department of Veterans Affairs (VA) national Corporate
Data Warehouse (CDW). The VA is the largest integrated health-
care system in the United States and comprises over 800 community
outpatient clinics, 150 hospitals and medical centers, and 120 nurs-
ing homes. We extracted data on all patients born between 1945 and
1965 who had at least 1 outpatient visit on or after 1 October 1999,
which included approximately half of all Veterans in care. This
study has been approved by the institutional review boards of the
VA Connecticut Healthcare System and Yale School of Medicine,
granted a waiver of informed consent, and deemed Health Insur-
ance Portability and Accountability Act compliant.
We included patients who did (gabapentin exposed) and did not
(gabapentin unexposed) receive gabapentin dispensed at VA phar-
macies. We did not consider other gabapentinoids (e.g., pregabalin
or gabapentin enacarbil) in this analysis as they are not commonly
prescribed in the VA. The gabapentin-exposed group included all
patients who received 2 or more gabapentin fills for at least 60 con-
tinuous days, for any indication, between January 1, 2002, and
March 30, 2015, from the following VA clinics: primary care, men-
tal health, neurology, general internal medicine, physical medicine
and rehabilitation services, pain, podiatry, orthopedics, women’s
clinic, psychiatry, substance use, and rheumatology. These clinics
were chosen because they were the source of most gabapentin pre-
scriptions. To ensure that unexposed patients came from the same
source population and had an equal opportunity to receive
gabapentin, we randomly selected one outpatient visit date per cal-
endar year to identify patients who attended one of the listed clinics
but never received gabapentin.
To allow us to follow exposed and unexposed patients over simi-
lar calendar time, we created an “index date” (also referred to as
“baseline”), which was defined as the first fill date for gabapentin-
exposed patients and the random outpatient visit date for unex-
posed patients. We identified the first prescription for gabapentin
during the study period and required a 180-day washout period so
as to identify new episodes of gabapentin exposure. We excluded
patients with no outpatient care in the year prior to their index date,
because of unknown recent medical history.
Propensity Score Model andMatching
In clinical trials, randomization is used to balance the distribution
of all potential confounders across treatment groups. To emulate
randomization using observational data, we used propensity score
matching. This was done by first modeling the probability (i.e.,
propensity) of receiving the treatment of interest as a function of all
measured covariates (Brookhart et al., 2006). Exposed patients were
then matched to unexposed patients with a similar propensity.
Matching by propensity score creates balanced exposure groups
similar to treatment allocation in a randomized controlled trial
(Austin, 2011), thus addressing concerns of confounding by indica-
tion. Unexposed patients with very low propensity and exposed
patients with very high propensity are unlikely to match, which is
akin to inclusion and exclusion criteria of a trial.
In our study, propensity scores were used to account for the proba-
bility of being prescribed gabapentin given a set of covariates that are
associated with both gabapentin receipt and neurologic adverse
events or associated only with neurologic adverse events. Propensity
scores (i.e., the predicted probability of gabapentin exposure) were
estimated using a multivariable logistic regression model. Variables
used in the propensity score models were selected a priori based on
clinical knowledge (Hernan et al., 2002) and included the following:
year of index date, age at baseline, race/ethnicity, smoking status,
body mass index at baseline, site prescribing pattern (the proportion
of patients who initiated gabapentin stratified by year), laboratory
values closest to the index date (including hemoglobin, international
normalized ratio, triglycerides), HCV status, HIV status, history of
seizure prior to baseline, diabetes complications severity index
(Young et al., 2008) at baseline, history of pain diagnoses prior to
baseline (including neuropathy, osteoarthritis, or pain in the abdo-
men, back, chest, extremity, or neck, headache, or fracture), and his-
tory of medical and psychiatric conditions prior to baseline (including
atrial fibrillation, myocardial infarction/coronary artery disease,
peripheral vascular disease, diabetes, nephrolithiasis, glomeru-
lonephritis, hyperlipidemia, pancreatitis, drug use disorders, posttrau-
matic stress disorder (PTSD), major or other depression, anxiety,
bipolar disorder, schizophrenia, and schizoaffective disorder). We
also included variables that captured attendance to clinics (including
primary care, dialysis, diabetic retinal screening, rheumatology, infec-
tious disease, nephrology, neurology, pain, allergy, chiropractic, den-
tal, diabetes, emergency department, electrocardiogram laboratory,
ophthalmology, hematology, oncology, homeless program, nutrition,
orthopedics, substance use, mental health, PTSD), frequency of all-
cause hospitalizations, and the total number of unique clinics visited
in the year prior to baseline. Lastly, variables denoting receipt of
other prescriptions at baseline to treat pain (including benzodi-
azepines, nonsteroidal anti-inflammatory drugs (NSAIDs), opioids,
muscle relaxants, and antidepressants) and seizures were included in
the model. Interaction terms were explored for significance, and 5
were kept in the final model (all p < 0.05). The model c-statistic was
0.89 indicating adequate discrimination between gabapentin-exposed
and gabapentin-unexposed patients (Hosmer and Lemeshow, 2000).
Since the distribution of propensity scores for exposed patients was
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different than that of unexposed patients, we used propensity score
matching to exclude nonexchangeable unexposed patients (i.e., those
with extremely low probability of gabapentin exposure) (Fig. 1)
(Spoendlin et al., 2016). Each exposed patient was matched to up to 5
unexposed patients in the same calendar year, using a greedy match-
ing algorithm (Cormen, 2009).
Clinical Subpopulations
For all conditions, we required 1 inpatient or 2 outpatient
diagnostic codes using the International Classification of
Diseases, 9th revision (ICD-9). HCV infection was defined by any
confirmatory HCV RNA test or ICD-9 diagnostic codes 070.41/
0.44; 070.51/0.54; 070.70/0.71; or V02.62. HIV status was deter-
mined by ICD-9 diagnostic codes 042, 044, or V08. AUD status
was determined by ICD-9 diagnostic codes 303.X or 305 to
305.03 at any time prior to baseline. The date of AUD diagnosis
was used to categorize AUD status into 3 mutually exclusive cat-
egories: never, lifetime (before the year prior to the index date),
or current (1 year prior to or 180 days after the index date).
Patients with both lifetime and current AUD diagnoses were clas-
sified as current.
Fig. 1. Distribution of propensity scores of gabapentin exposure before and after propensity score matching. Panel (A): Before matching. Panel (B):
After matching
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Neurologic Adverse Events and Follow-Up
We used ICD-9 codes to define falls or fractures (805.2X-805.7,
812.XX, 820.XX, E882-E885, E888) and altered mental status (291,
291.1, 292.81, 293, 293.1, 298.2, 780.09, 780.97). These ICD-9 codes
were selected to be consistent with previous literature (Hope et al.,
2014; Pugh et al., 2015; Thyagarajan et al., 2013; Womack et al.,
2011). We excluded patients diagnosed with any of these events in
the year preceding their index date.
Patients were followed a maximum of 2 years from their index
date to the first occurrence of any outcome, last VA visit, death, or
September 30, 2015. Additionally, gabapentin-exposed patients
were censored 30 days after the end of their last gabapentin pre-
scription (allowing for a maximum 30-day gap between fills). To
ensure equal follow-up time within matched sets, unexposed
patients were censored at the total follow-up time of their matched
exposed patient.
Statistical Analyses
We used standardized differences (Austin, 2009) to examine bal-
ance between exposed and unexposed patients included in the full
and propensity-score matched sample. We estimated incidence rates
(IR) for exposed and unexposed patients for each outcome. We then
used multivariable Poisson regression models to estimate exposure
rate ratios (RR) and 95% confidence intervals (CI) for the relative
risk of a neurologic adverse event in association with exposure to
gabapentin. We performed subgroup analyses by age (<60
or ≥ 60 years), race/ethnicity (white, black, or Hispanic), sex (male
or female), HCV status, HIV status, and AUD (never, lifetime, or
current). Finally, we investigated association of initial gabapentin
dose with neurologic adverse events (<600 mg, 600 to 899 mg, 900
to 1,199 mg, 1,200 to 1,799 mg, 1,800 to 2,399 mg,
and ≥ 2,400 mg). All statistical analyses were performed using SAS
version 9.4 (SAS Institute Inc., Cary, NC).
RESULTS
Sample
We identified 431,920 gabapentin-exposed patients and
2,576,410 gabapentin-unexposed patients eligible for propen-
sity score matching. The matching process resulted in 54,878
(39.1%) gabapentin-exposed patients with 5 unexposed
matches, 8,475 (6.0%) with 412,577 (9.0%) with 321,007
(15.0%) with 2, and 43,373 (30.9%) with 1 matched unex-
posed patient. Thus, the analytic sample consisted of 140,310
exposed and 431,408 unexposed patients.
Before propensity score matching, the distribution of base-
line characteristics significantly differed between gabapentin-
exposed and gabapentin-unexposed patients (Table 1). Com-
pared to gabapentin-exposed patients who matched to unex-
posed patients, gabapentin-exposed patients who did not
match had similar proportions with HCV, HIV, or current
AUD, were more likely to have comorbidities, particularly
neuropathic pain (28%) and be prescribed other medications
particularly opioids (30%) and muscle relaxants (18%)
(Table S1). The median (interquartile range) propensity
score in exposed patients who did not match was 0.11 (0.03
to 0.27), higher than those who were matched 0.07 (0.03 to
0.13). In the matched sample, gabapentin-exposed and gaba-
pentin-unexposed patients were well balanced. Median
follow-up time was 137 days (IQR 100 to 269 days). Among
exposed patients in the analytic sample, 38%, 20%, 28%,
7%, 5%, and 3% were initially prescribed daily doses of
gabapentin <600 mg, 600 to 899 mg, 900 to 1,199 mg, 1,200
to 1,799 mg, 1,800 to 2,399 mg, and ≥2,400 mg, respectively.
Rates of Adverse Events
Overall in the matched sample, the incidence rate for falls
or fractures was 1.81 per 100 person-years (PY) among
exposed and 1.34/100 PY among unexposed patients, and
for altered mental status 1.08/100 PY among exposed and
0.97/100 PY among unexposed patients (Table 2). Com-
pared to unexposed patients, those exposed to gabapentin
were 35% more likely (95% confidence interval [CI] 1.28 to
1.44) to experience a fall or fracture and 12% more likely
(95% CI 1.04 to 1.20) to experience altered mental status
(Fig. 2).
Subgroup Analyses
Compared to the overall sample, incidence rates for both
neurologic adverse events were greater among those with
HCV infection, HIV infection, or current AUD diagnosis.
Although absolute incidence was higher, the relative risk
associated with gabapentin exposure was attenuated
(Table 2). The rate of falls or fractures for patients with
HCV infection was 2.71/100 PY among exposed and 2.42/
100 PY among unexposed (rate ratio [RR] 1.12, 95% CI 0.94
to 1.32). For patients with HIV infection, rates were 2.00/100
PY among exposed and 1.50/100 PY among unexposed (RR
1.34, 95% CI 0.74 to 2.43). For patients with current AUD
diagnosis, rates were 2.84/100 PY among exposed and 2.62/
100 PY among unexposed (RR 1.08, 95% CI 0.94 to 1.25).
In all other subgroups, excess risk associated with gabapen-
tin exposure persisted (Fig. 2). Similar results were observed
for altered mental status in the various subgroups.
We further stratified exposed patients by dose of gabapen-
tin. There was a clear dose–response relationship for falls or
fractures with relative risks increasing from 1.23 (95% CI
1.13 to 1.34) for <600 mg/d to 1.90 (95% CI 1.50 to 2.40)
for ≥ 2,400 mg/d. (Table 3). Patients were at elevated risk
for altered mental status at doses ≥ 600 mg/d; however,
associations in dose categories ≥ 1,800 mg/d were not statis-
tically significant, possibly due to few events in these higher
dose categories.
DISCUSSION
In this national study of over 500,000 patients aged
between 36 and 70 years, gabapentin-exposed patients had
increased incidence of neurologic adverse events compared
to unexposed patients and were 35% more likely to experi-
ence a fall or fracture and 12% more likely to experience
altered mental status. Patients with HCV infection, HIV
infection, or a current AUD diagnosis had elevated rates of
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all neurologic adverse events compared to overall rates, but
did not demonstrate increased risk of neurologic events when
exposed to gabapentin. Our findings also showed a positive
dose–response relationship for falls or fractures at all doses
with greatest risk of occurring at gabapentin
doses ≥ 2,400 mg/d and increased risk of altered mental sta-
tus at doses ≥ 600 mg/d.
Our overall finding that gabapentin-exposed patients were
more likely to experience neurologic adverse events is consis-
tent with several studies. A systematic review and meta-anal-
ysis evaluating the safety of gabapentinoids in chronic low
back pain found that patients receiving gabapentin were sig-
nificantly more likely to report dizziness, fatigue, and difficul-
ties with mentation compared to placebo (Shanthanna et al.,
2017). Similarly, a Cochrane Collaborative review of 37 ran-
domized controlled trials examining gabapentin for chronic
neuropathic pain found that adults taking gabapentin experi-
enced significantly more gait disturbance, dizziness, and som-
nolence compared to those receiving placebo (Wiffen et al.,
2017). A meta-analysis of 7 randomized controlled trials
involving a total of 2,039 patients found that patients given
gabapentin for the treatment of postherpetic neuralgia were
significantly more likely to experience ataxia, dizziness, and
somnolence (Meng et al., 2014). Another meta-analysis of 7
randomized controlled trials assessing safety and efficacy of
different doses of gabapentin for postherpetic neuralgia
found that gabapentin at 1,800 mg/d was significantly asso-
ciated with dizziness and somnolence and the risk of these
adverse events increased at doses of 2,400 to 3,600 mg/d
(Wang and Zhu, 2017). Unlike these studies that examined
adverse effects such as dizziness and ataxia, we focused on
falls and fractures, which are less reported in the literature.
One large observational study among 140,899 Medicare-cov-
ered adults receiving hemodialysis found that gabapentin
was associated with 55% increased risk of falls and 38%
increased risk of fractures (Ishida et al., 2018).
Despite evidence demonstrating gabapentin’s neurologic
adverse events especially when used for pain, its use for treat-
ing individuals with AUD is generally considered safe. One
randomized controlled trial evaluating the impact of gaba-
pentin dose on alcohol-related outcomes among 150 patients
with current AUD reported no significant differences in the
Table 1. Distribution of Baseline Characteristics in Gabapentin-Exposed and Gabapentin-Unexposed Patients Before and After Propensity Score (PS)






Exposed Unexposed Exposed Unexposed
n = 431,920 n = 2,576,410a n = 140,310 n = 140,310 a
Age
<60 267,328 (61.9) 1,572,375 (61.0) <0.01 88,980 (63.4) 87,641 (62.5) 0.02
≥60 164,592 (38.1) 1,004,035 (39.0) 51,330 (36.6) 52,669 (37.5)
Race/ethnicity
White 302,615 (70.1) 1,631,928 (63.3) 0.16 97,513 (69.5) 95,534 (68.1) 0.07
Black 76,133 (17.6) 454,832 (17.7) 24,815 (17.7) 25,382 (18.1)
Hispanic 23,167 (5.4) 117,604 (4.6) 7,512 (5.4) 7,332 (5.2)
Other 13,518 (3.1) 75,734 (2.9) 4,454 (3.2) 4,194 (3.0)
Missing 16,487 (3.8) 296,312 (11.5) 6,016 (4.3) 7,867 (5.6)
Male sex 401,937 (93.1) 2,425,510 (94.1) 0.03 131,007 (93.4) 131,835 (94.0) 0.02
HCV+ 39,864 (9.2) 115,976 (4.5) 0.14 12,384 (8.8) 13,271 (9.5) 0.01
HIV+ 4,193 (1.0) 18,257 (0.7) 0.03 1,381 (1.0) 1,616 (1.2) 0.01
AUD
Never 337,384 (78.1) 2,290,858 (88.9) 0.20 111,937 (79.8) 108,671 (77.5) 0.02
Lifetime 43,411 (10.1) 140,080 (5.4) 13,336 (9.5) 14,471 (10.3)
Current 51,125 (11.8) 145,472 (5.7) 15,037 (10.7) 17,169 (12.2)
Any hospitalization 68,054 (15.8) 160,016 (6.2) 0.29 20,494 (14.6) 22,748 (16.2) 0.03
Conditions
Seizure 10,885 (2.5) 32,187 (1.3) 0.10 3,166 (2.3) 3,960 (2.8) <0.01
Diabetes 165,085 (38.2) 395,961 (15.4) 0.42 51,017 (36.4) 50,963 (36.3) 0.09
Anxiety 82,884 (19.2) 184,599 (7.2) 0.27 24,277 (17.3) 23,186 (16.5) 0.07
Neuropathic pain 111,164 (25.7) 95,761 (3.7) 0.59 28,524 (20.3) 25,754 (18.4) 0.19
Any chronic pain 401,994 (93.1) 1,751,616 (68.0) 0.41 129,072 (92.0) 128,342 (91.5) 0.08
Other prescription
Benzodiazepines 61,015 (14.1) 92,721 (3.6) 0.32 17,786 (12.7) 17,950 (12.8) 0.09
Opioid 119,878 (27.8) 121,218 (4.7) 0.62 32,163 (22.9) 31,987 (22.8) 0.16
Antidepressant 51,802 (12.0) 53,710 (2.1) 0.36 13,697 (9.8) 12,783 (9.1) 0.12
NSAID 207,325 (48.0) 374,108 (14.5) 0.66 62,935 (44.9) 64,879 (46.2) 0.11
Muscle relaxant 69,626 (16.1) 60,830 (2.4) 0.46 17,755 (12.7) 17,220 (12.3) 0.13
Anticonvulsant 12,387 (2.9) 22,179 (0.9) 0.14 3,631 (2.6) 3,665 (2.6) 0.04
PS, propensity score; HIV, human immunodeficiency virus; HCV, hepatitis C virus; AUD, alcohol use disorder; NSAID, nonsteroidal anti-inflammatory
drug.
aUnexposed matches were weighted according to number of matches.
All statistics reported as n (%); up to 5 unexposed patients were matched to each exposed patient.
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number, severity, or type of adverse events between patients
receiving placebo, gabapentin 900 mg/d, or gabapentin
1,800 mg/d, although 4 of the 5 identified drug-related
adverse events occurred in gabapentin-exposed patients (fa-
tigue and headache) (Mason et al., 2014). A meta-analysis of
7 placebo-controlled randomized controlled trials evaluating
efficacy of gabapentin for treating AUD also found no seri-
ous adverse events reported with gabapentin exposure
(Kranzler et al., 2019). Similarly, we found less than 10%
excess risk (not statistically significant) of adverse events
associated with gabapentin exposure among patients with
current AUD. However, a recent randomized controlled trial
examining the efficacy of gabapentin on AUD treatment out-
comes among 90 patients with alcohol withdrawal symptoms
found significantly more reports of mild to moderate dizzi-
ness in those receiving gabapentin versus placebo (n = 25 vs.
n = 15; p = 0.02) (Anton et al., 2020). Additionally, a multi-
site clinical trial evaluating the safety and efficacy of gaba-
pentin enacarbil extended-release (GE-XR) in 346
participants with moderate to severe AUD reported no
serious adverse events related to medication use, but did find
significantly greater rates of fatigue (25.9% vs. 15.5%;
p = 0.022), somnolence (17.6% vs 9.5%; p = 0.038), and tre-
mor (5.9% vs. 0.6%; p = 0.010), as well as a nonsignificant
increase for dizziness (21.2% vs. 13.7%; p = 0.085) in the
GE-XR group versus placebo group (Falk et al., 2019).
Compared to overall rates, we found that patients with
current AUD had greater rates of neurologic adverse events
regardless of gabapentin exposure, suggesting that these
patients represent a particularly vulnerable population at
risk for falls, fractures, and altered mental status. Given the
growing body of evidence supporting gabapentin’s safety
and efficacy in treating AUD (Anton et al., 2020; Kranzler
et al., 2019; Mason et al., 2014), these baseline risks among
individuals with current AUD should be considered along-
side the potential benefits gabapentin treatment in this popu-
lation. Among trials that found significantly greater rates of
adverse events among gabapentin-exposed patients, these
events were reported as mild to moderate (Anton et al., 2020;
Falk et al., 2019; Pani et al., 2014). Furthermore, Anton and
Table 2. Rates of Neurologic Adverse Events Among 140,310 Gabapentin-Exposed Patients and 1:5 Propensity-Score Matched Unexposed Controls
Exposed
Fall or fracture Altered mental status
# Events Rate (95%CI) RR (95%CI) p-value # Events Rate (95% CI) RR (95%CI) p-value
Overall Yes 1,663 1.81 (1.73 to 1.90) 1.35 (1.28 to 1.44) <0.0001 1,001 1.08 (1.02 to 1.15) 1.12 (1.04 to 1.20) 0.0027
No 3,547 1.34 (1.29 to 1.38) ref 2,600 0.97 (0.93 to 1.01) ref
Age, years
<60 Yes 992 1.79 (1.69 to 1.91) 1.34 (1.25 to 1.45) <0.0001 558 1.00 (0.92 to 1.09) 1.10 (1.00 to 1.21) 0.0578
No 2,162 1.34 (1.28 to 1.39) ref 1,488 0.91 (0.87 to 0.96) ref
≥60 Yes 671 1.83 (1.70 to 1.98) 1.37 (1.25 to 1.51) <0.0001 443 1.21 (1.10 to 1.32) 1.14 (1.02 to 1.27) 0.0193
No 1,385 1.34 (1.27 to 1.41) ref 1,112 1.06 (1.00 to 1.12) ref
Race/ethnicity
White Yes 1,276 1.88 (1.78 to 1.99) 1.31 (1.23 to 1.40) <0.0001 743 1.09 (1.01 to 1.17) 1.10 (1.01 to 1.20) 0.0249
No 2,588 1.43 (1.38 to 1.49) ref 1,798 0.99 (0.94 to 1.04) ref
Black Yes 209 1.60 (1.40 to 1.83) 1.53 (1.30 to 1.79) <0.0001 151 1.15 (0.98 to 1.35) 1.32 (1.09 to 1.58) 0.0036
No 522 1.05 (0.96 to 1.14) ref 449 0.88 (0.80 to 0.96) ref
Hispanic Yes 84 1.92 (1.55 to 2.38) 1.59 (1.22 to 2.06) 0.0005 37 0.84 (0.61 to 1.16) 0.91 (0.63 to 1.31) 0.6220
No 173 1.21 (1.04 to 1.41) ref 134 0.92 (0.78 to 1.09) ref
Sex
Male Yes 1,528 1.77 (1.69 to 1.86) 1.36 (1.28 to 1.44) <0.0001 954 1.10 (1.03 to 1.17) 1.11 (1.03 to 1.19) 0.0069
No 3,259 1.31 (1.26 to 1.35) ref 2,500 0.99 (0.96 to 1.03) ref
Female Yes 135 2.38 (2.01 to 2.82) 1.35 (1.10 to 1.65) 0.0041 47 0.82 (0.62 to 1.10) 1.36 (0.96 to 1.92) 0.0817
No 288 1.77 (1.58 to 1.98) ref 100 0.61 (0.50 to 0.74) ref
HCV infection
Uninfected Yes 1,478 1.74 (1.65 to 1.83) 1.40 (1.32 to 1.49) <0.0001 832 0.97 (0.91 to 1.04) 1.16 (1.07 to 1.26) 0.0003
No 3,028 1.24 (1.20 to 1.29) ref 2,069 0.84 (0.80 to 0.88) ref
HCV+ Yes 185 2.71 (2.34 to 3.12) 1.12 (0.94 to 1.32) 0.1956 169 2.47 (2.12 to 2.87) 1.00 (0.84 to 1.19) 0.9865
No 519 2.42 (2.22 to 2.64) ref 531 2.46 (2.26 to 2.68) ref
HIV infection
Uninfected Yes 1,648 1.81 (1.72 to 1.90) 1.36 (1.28 to 1.44) <0.0001 990 1.08 (1.02 to 1.15) 1.13 (1.05 to 1.21) 0.0015
No 3,507 1.33 (1.29 to 1.38) ref 2,548 0.96 (0.92 to 1.00) ref
HIV+ Yes 15 2.00 (1.21 to 3.32) 1.34 (0.74 to 2.43) 0.3333 11 1.46 (0.81 to 2.64) 0.77 (0.40 to 1.47) 0.4210
No 40 1.50 (1.10 to 2.04) ref 52 1.91 (1.45 to 2.51) ref
AUD
Never Yes 1,263 1.68 (1.59 to 1.77) 1.46 (1.36 to 1.56) <0.0001 680 0.90 (0.83 to 0.97) 1.20 (1.09 to 1.31) <0.0001
No 2,418 1.15 (1.10 to 1.19) ref 1,598 0.75 (0.71 to 0.79) ref
Lifetime Yes 166 2.02 (1.73 to 2.35) 1.41 (1.18 to 1.70) 0.0002 108 1.31 (1.08 to 1.58) 1.13 (0.91 to 1.41) 0.2803
No 371 1.43 (1.29 to 1.58) ref 307 1.16 (1.04 to 1.30) ref
Current Yes 234 2.84 (2.49 to 3.22) 1.08 (0.94 to 1.25) 0.2869 213 2.57 (2.25 to 2.94) 1.07 (0.92 to 1.25) 0.3661
No 758 2.62 (2.44 to 2.81) ref 695 2.40 (2.23 to 2.58) ref
AUD, alcohol use disorder; CI, confidence interval; HIV, human immunodeficiency virus; HCV, hepatitis C virus; RR, rate ratio.
Rates per 100 person-years.
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colleagues (2020) reported significantly more dizziness in
those receiving gabapentin versus placebo, but the presence
or absence of dizziness did not significantly account for gaba-
pentin’s effectiveness. Importantly, these clinical trials
included only medically stable patients who were not using
substances other than alcohol and nicotine, and thus may
not reflect our study sample or generalize to other treatment
settings.
Similar to patients with current AUD, our subgroup anal-
ysis of patients with HCV and HIV demonstrated elevated
incidence of adverse events regardless of gabapentin expo-
sure, which may reflect baseline risk for these adverse
Fig. 2. Associations between gabapentin exposure and neurologic adverse events. Panel (A): Fall or fracture. Panel (B): Altered mental status. Note:
● = p ≤ 0.05; ○ = p > 0.05. Abbreviations: RR, rate ratio; CI, confidence interval; HCV, hepatitis C virus; HIV, human immunodeficiency virus; AUD,
alcohol use disorder.
Table 3. Dose-Specific Rates of Neurologic Adverse Events Among 140,310 Gabapentin-Exposed Patients and 1:5 Propensity-Score Matched
Unexposed Controls
Fall or fracture Altered mental status
# Events Rate (95%CI) RR (95% CI) p-value # Events Rate (95%CI) RR (95% CI) p-value
Dose, milligrams
≥2,400 71 2.56 (2.03 to 3.23) 1.90 (1.50 to 2.40) <0.0001 33 1.19 (0.84 to 1.67) 1.21 (0.86 to 1.71) 0.2724
1,800 to 2,399 92 1.92 (1.57 to 2.36) 1.43 (1.16 to 1.76) 0.0008 60 1.25 (0.97 to 1.61) 1.28 (0.99 to 1.65) 0.0597
1,200 to 1,799 124 2.05 (1.72 to 2.45) 1.52 (1.27 to 1.82) <0.0001 80 1.32 (1.06 to 1.65) 1.35 (1.08 to 1.69) 0.0082
900 to 1,199 466 1.98 (1.80 to 2.16) 1.47 (1.33 to 1.62) <0.0001 294 1.25 (1.11 to 1.40) 1.27 (1.13 to 1.43) <0.0001
600 to 899 320 1.76 (1.58 to 1.96) 1.31 (1.17 to 1.47) <0.0001 215 1.18 (1.03 to 1.35) 1.21 (1.05 to 1.39) 0.0082
<600 590 1.66 (1.53 to 1.79) 1.23 (1.13 to 1.34) <0.0001 319 0.90 (0.80 to 1.00) 0.91 (0.81 to 1.03) 0.1260
Unexposed 3,545 1.35 (1.30 to 1.39) Ref 2,580 0.98 (0.94 to 1.02) Ref
RR, rate ratio; CI, confidence interval.
Rates per 100 person-years.
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outcomes due to increased rates of medical and psychiatric
comorbidities and potential medication interactions (Evon
et al., 2018; Ruzicka et al., 2019). In contrast to our findings,
one small randomized controlled trial comparing the effect
of gabapentin with placebo in HIV-associated sensory neu-
ropathy found that participants receiving gabapentin were
more likely to report somnolence (12/15 for gabapentin and
2/11 for placebo; p = 0.006), dizziness (9/15 for gabapentin
and 5/11 for placebo; p = 0.305), and gait disturbance (7/15
for gabapentin and 3/11 for placebo; p = 0.357) (Hahn et al.,
2004).
Notably, we observed a dose–response relationship for
adverse events consistent with findings of a meta-analysis
examining gabapentin safety among patients with posther-
petic neuralgia (Wang and Zhu, 2017). This study reported
increased risk of adverse outcomes starting at gabapentin
doses of ≥ 1,800 mg/d, whereas we demonstrated increased
risk at lower doses of ≥ 600 mg/d. These findings are partic-
ularly relevant when considering the use of gabapentin to
treat AUD, as current evidence suggests greater impact of
gabapentin on reducing alcohol consumption at higher doses
of ≥ 1,500 mg/d (Mason et al., 2014; Rentsch et al., 2019).
However, it is important to note that gabapentin has been
shown to improve AUD outcomes even at doses as low as
900 mg/d (Mason et al., 2014), which may reduce the risk of
adverse consequences. Our finding of continued gabapentin
prescribing at low or subtherapeutic doses despite the appar-
ent risk of adverse events may reflect a desire among clini-
cians to prescribe nonopioid medications for pain
(Goodman and Brett, 2017).
This research differs from recent safety studies of gabapen-
tin use in a number of important ways. First, we evaluated
the association of gabapentin with neurologic adverse events
in a real-world setting among patients who were prescribed
gabapentin for any indication. Second, we addressed
methodological challenges inherent to observational study
designs by applying uniform exclusion criteria for exposed
and unexposed patients, evaluating incident exposures, set-
ting an index date for exposed and unexposed patients, and
using propensity score matching to account for confounding
by indication. Finally, our study included a large sample size
of approximately 140,000 gabapentin-exposed patients,
which to our knowledge is the largest study to date examin-
ing gabapentin safety in a real-world setting.
There are limitations to our work. Due to characteristics
of individuals who access care in the VA healthcare system,
our sample was enriched with men and patients with multiple
medical comorbidities, which may not generalize to other
clinical settings. Some of our analyses lacked adequate power
due to small samples in certain patient subgroups, including
patients with HIV infection. We were also unable to obtain
proxy measures to capture adverse outcomes that were not
diagnosed using ICD-9 codes, which may underestimate the
rate of adverse events. Only one-third of the gabapentin-ex-
posed patients in our cohort were propensity-score matched,
although there was no significant difference of HCV, HIV,
or AUD prevalence between those who did and did not
match. Our findings may not generalize to those with stron-
ger indications for gabapentin. Despite these limitations, we
believe our findings provide novel information on the safety
of gabapentin use and highlight the risk of falls, fractures,
and altered mental status among patients from a large
national integrated healthcare system.
This work has important implications for researchers and
clinicians. We used real-world data to demonstrate that
gabapentin is associated with increased risk of falls, frac-
tures, and altered mental status at doses ≥ 600 mg/d, which
should be carefully considered by clinicians. The widespread
prescribing of gabapentin for various conditions, which con-
trasts with the limited use of FDA-approved medications for
AUD, suggests that clinicians are familiar with gabapentin
and may feel more comfortable prescribing it for AUD treat-
ment. Such comfort with prescribing gabapentin paired with
growing evidence to support its efficacy in treating AUD
(Anton et al., 2020; Kranzler et al., 2019; Mason et al., 2014;
Pani et al., 2014) may help expand the number of individuals
with AUD receiving effective medication treatment. How-
ever, these possible benefits must be weighed against poten-
tial risks. There is evidence suggesting nonmedical use of
gabapentin to achieve euphoric effects, particularly in indi-
viduals with substance use disorders (Peckham et al., 2017;
Smith et al., 2016). Although gabapentin misuse has been
reported primarily in individuals with opioid and polysub-
stance use rather than in those with AUD alone, clinicians
should consider monitoring for medication misuse and diver-
sion when prescribing gabapentin. Although we did not find
an excess risk of adverse events among gabapentin-exposed
patients with current AUD, our findings indicate that these
patients are predisposed to falls, fractures, and altered men-
tal status that may reflect complications of acute and chronic
alcohol use, such as intoxicating effects, advanced liver dis-
ease, and peripheral neuropathy. More research is needed to
clarify predisposing risk factors and drug interactions that
may increase these neurologic adverse events in patients with
AUD to guide risk stratification and to examine gabapentin
safety at higher doses associated with improved AUD out-
comes.
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SUPPORTING INFORMATION
Additional supporting information may be found online
in the Supporting Information section at the end of the arti-
cle.
Table S1 Distribution of baseline characteristics in gaba-
pentin exposed patients who did and did not propensity
score (PS) match.
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